{"ATC Code":"N04AA02","Abbreviation":"","Aliases":["Akineton","Biperidene","Biperidine","Biperideno","Biperidenum","Beperiden","KL 373","α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol","Akineton-","1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1","3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol","1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol","α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-1-piperidinepropanol","1-Piperidinepropanol, α-5-norbornen-2-yl-α-phenyl-","3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1)","1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol","1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol","1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-","1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-, hydrochloride","Ncgc00182965-01","Sr-05000001649","1-Piperidinepropanol, α-bicyclo(2.2.1)hept-5-en-2-yl-α-phenyl-","1-(Bicyclo(2.2.1)hept-5-en-2α-yl)-1-phenyl-3-piperidinopropanol","α-(Bicyclo(2.2.1)hept-5-en-2-yl)-α-phenyl-1-piperidino propanol","Akinophyl"],"Biological Half-Life":"A single-blind cross-over design was employed with placebo and biperiden (4 mg as commercially available tablets). After a lag time of 0.5 hr, biperiden was rapidly absorbed with a half-life of 0.3 hr, ... Biperiden showed good tissue penetration (distribution half-life 0.6 hr; ratio of total to central distribution volume 9.6), the terminal half-life time of plasma concentration was 18 hr, ... .","CAS":"514-65-8","ChEBI":"CHEBI:3112","ChEMBL":"CHEMBL1101","ChemicalClasses":["piperidine"],"Classes":["Anticholinergic"],"Color/Form":"Crystals","Drug Classes":"Antiparkinson Agents","Drug Indication":"For use as an adjunct in the therapy of all forms of parkinsonism and control of extrapyramidal disorders secondary to neuroleptic drug therapy.","Drug Warnings":"Isolated instances of mental confusion, euphoria, agitation and disturbed behavior have been reported in susceptible patients. Also, the central anticholinergic syndrome can occur as an adverse reaction to properly prescribed anticholinergic medication, although it is more frequently due to overdosage. It may also result from concomitant administration of an anticholinergic agent and a drug that has secondary anticholinergic actions. Caution should be observed in patients with manifest glaucoma, though no prohibitive rise in intraocular pressure has been noted following either oral or parenteral administration. Patients with prostatism, epilepsy or cardiac arrhythmia should be given this drug with caution. Occasionally, drowsiness may occur, and patients who drive a car or operate any other potentially dangerous machinery should be warned of this possibility. As with other drugs action on the central nervous system, the consumption of alcohol should be avoided during Akineton therapy.","EINECS":"208-184-6","Esters":[],"European Community (EC) Number":"208-184-6","FDA Pharmacological Classification":"0FRP6G56LD","Formating":[],"HMDB ID":"HMDB0014948","HeavyAtomCount":23,"Human Drugs":"Human drug -\u003e Discontinued","IUPACName":"1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol","InChI":"InChI=1S/C21H29NO/c23-21(19-7-3-1-4-8-19,11-14-22-12-5-2-6-13-22)20-16-17-9-10-18(20)15-17/h1,3-4,7-10,17-18,20,23H,2,5-6,11-16H2","InChIKey":"YSXKPIUOCJLQIE-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents used in the treatment of Parkinson\u0026apos;s disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)","Melting Point":"101 °C","MolecularFormula":"C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e29\u003c/sub\u003eNO","MolecularWeight":"311.5 g/mol","Pharmacodynamics":"Biperiden is a weak peripheral anticholinergic agent. It has, therefore, some antisecretory, antispasmodic and mydriatic effects. In addition, biperiden possesses nicotinolytic activity. The parenteral form of biperiden is an effective and reliable agent for the treatment of acute episodes of extrapyramidal disturbances sometimes seen during treatment with neuroleptic agents. Akathisia, akinesia, dyskinetic tremors, rigor, oculogyric crisis, spasmodic torticollis, and profuse sweating are markedly reduced or eliminated. With parenteral biperiden, these drug-induced disturbances are rapidly brought under control.","Physical Description":"Solid","PubChemId":2381,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Biperiden","Name":"Biperiden","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q414914","Name":"Biperiden","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00810","Name":"Biperiden","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/2381","Name":"Biperiden","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1101","Name":"Biperiden","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3112","Name":"Biperiden","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=514-65-8","Name":"Biperiden","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014948","Name":"Biperiden","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07941","Name":"Biperiden","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/0FRP6G56LD","Name":"Biperiden","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6022680","Name":"Biperiden","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 2381, Biperiden. Accessed July 7, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/2381\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/2381\u003c/a\u003e"],"SMILES":"C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O","SaltData":[],"Salts":[],"Solubility":"Fluffy white powder, mp 238 °C. Solubility in water (mg/100 mL) at 30 °C: 220 (ph 3.8), 280 (pH 5.5), 290 (pH 6.7), 264 (pH 7.9), 244 (pH 9.2-10.1) /Hydrochloride/","StereoisomerData":[{"Aliases":["Akineton","Biperidene","Biperidine","Biperideno","Biperidenum","Beperiden","KL 373","α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol","Akineton-","1-Bicycloheptenyl-1-phenyl-3-piperidino-propanol-1","3-Piperidino-1-phenyl-1-bicycloheptenyl-1-propanol","1-(bicyclo[2.2.1]hept-5-en-2-yl)-1-phenyl-3-(piperidin-1-yl)propan-1-ol","α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-1-piperidinepropanol","1-Piperidinepropanol, α-5-norbornen-2-yl-α-phenyl-","3-Piperidino-1-phenyl-1-bicyclo(2.2.1)hepten-(5)-yl-propanol-(1)","1-(5-bicyclo[2.2.1]hept-2-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol","1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol","1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-","1-Piperidinepropanol, α-bicyclo[2.2.1]hept-5-en-2-yl-α-phenyl-, hydrochloride","Ncgc00182965-01","Sr-05000001649","1-Piperidinepropanol, α-bicyclo(2.2.1)hept-5-en-2-yl-α-phenyl-","1-(Bicyclo(2.2.1)hept-5-en-2α-yl)-1-phenyl-3-piperidinopropanol","α-(Bicyclo(2.2.1)hept-5-en-2-yl)-α-phenyl-1-piperidino propanol","Akinophyl"],"PubChemId":2381,"SMILES":"C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O","Structure":null,"Title":null,"UNII":"0FRP6G56LD"}],"Stereoisomers":["Biperiden"],"Structure":"\u003csvg  preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 101.067 86.716\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h102v87H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath d=\"m100.029 32.88-7.62-13.208M92.409 19.672h-15.24M77.169 19.672l-5.507 9.546M71.662 36.543l5.507 9.545M77.169 46.088h15.24M100.029 32.88l-7.62 13.208M66.208 32.88H54.309M54.309 32.88l-7.62 13.199M46.689 46.079h-15.24M31.449 46.079l-7.62 13.198M23.829 59.277l7.618 13.199M31.447 72.476l-7.63 13.202M23.817 85.678l-3.571-15.535M20.246 70.143 8.581 59.279M23.829 59.277l-15.248.002M8.581 59.279 1.038 72.43\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m1.038 72.43 7.618 13.2M3.851 72.427l6.216 10.769\"/\u003e\u003c/g\u003e\u003cpath d=\"M23.817 85.678 8.656 85.63M31.449 46.079l2.647-15.009\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m22.411 21.272 11.685 9.798M25.057 20.309l9.527 7.989\"/\u003e\u003c/g\u003e\u003cpath d=\"m22.411 21.272 2.647-15.008\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m39.388 1.053-14.33 5.211M38.9 3.825 27.215 8.074\"/\u003e\u003c/g\u003e\u003cpath d=\"m39.388 1.053 11.685 9.798\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m48.426 25.859 2.647-15.008M46.269 24.049l2.158-12.235\"/\u003e\u003c/g\u003e\u003cpath d=\"m34.096 31.07 14.33-5.211M31.449 46.079l-10.772-3.921\" class=\"bond\"/\u003e\u003cpath fill=\"#3050f8\" stroke=\"none\" d=\"M71.49 35.33h-.72l-2.62-4.066h-.03l.03.595q.024.358.024.733v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.328-.024-.476q-.006-.262-.006-.482v-2.768h.578z\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M19.387 40.863q0 .756-.255 1.328-.256.565-.757.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881t1.274-.316q.732 0 1.232.316.501.309.757.875.255.565.255 1.327m-3.863 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M14.307 43.316h-.619V41.03h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#3050f8\" d=\"m71.662 29.218 2.754-4.773M71.662 36.543l2.754 4.773M66.208 32.88h-5.95\" class=\"hi\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m20.677 42.158 5.386 1.96M20.677 42.158l5.386 1.96\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","StructureBase64":"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","Subjective Effects":null,"Therapeutic Uses":"Biperiden is used for the adjunctive treatment of all forms of parkinsonian syndrome, in which it appears to be more effective in the postencephalitic and idiopathic than in the arteriosclerotic types. Biperiden usually relieves muscle rigidity, reduces sweating and salivation, and improves gait and, to a lesser extent, tremor. Biperiden also is used for the relief of parkinsonian signs and symptoms of antipsychotic agent-induced (e.g., phenothiazines) extrapyramidal reactions. Although it has been used as adjunctive therapy in the management of other disorders of the extrapyramidal system and of unrelated spastic conditions such as multiple sclerosis, cerebral palsy, and spinal cord injuries, the value of the drug in these conditions requires further investigation.","Title":"Biperiden","UNII":"0FRP6G56LD","Wikidata":"Q414914","Wikipedia":"Biperiden","XLogP":4.3}